CYTOPROTECTOR ROLE IN THE MANAGEMENT OF ARTERIAL HYPERTENSION TREATED WITH ENALAPRIL

• Main Authors: F. E. Khebodarov, V. P. Mikhin
• Format: Article
• Language: Russian
• Published: «FIRMA «SILICEA» LLC 2009-10-01
• Series: Российский кардиологический журнал
• Subjects: arterial hypertension; cardiac cytoprotectors; enalapril
• Online Access: https://russjcardiol.elpub.ru/jour/article/view/1386

The study investigated the effects of cardiac cytoprotectors – mildronate and trimetazidine, combined with ACE therapy, on lipid peroxidation product levels, endothelial function, circadian blood pressure (BP) profile, left ventricular myocardium, and intracardiac hemodynamics in patients with arterial hypertension (AH). It was demonstrated that in AH patients, the combination of mildronate and enalapril facilitated lipid peroxidation reduction, endothelial function and circadian BP normalization, as well as improvement of left ventricular morphology and function. The combination of trimetazidine and enalapril did not improve the effectiveness of antihypertensive therapy.